Characteristics of Immunoglobulin Products Used to Treat Primary Immunodeficiency Diseases Booklet
Click to download or order the booklet
IDF MAC Resolution on Product Choice for Immunoglobulin Replacement Therapy
In November 2011, the IDF Medical Advisory Committee wrote a resolution regarding formulary changes that limit a physician’s ability to determine the most appropriate immunoglobulin replacement therapy. Restricting access of subscribers to only one or two product/formulations of replacement immunoglobulin regardless of the particular product the patient may currently be receiving poses an unjustified safety risk for patients. Read the entire resolution: IDF MAC Resolution on Product Choice for Immunoglobulin Replacement Therapy – 1/26/11